Aethlon Medical Inc（AEMD）股票分析AEMDAethlon Medical Inc

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Aethlon Medical Inc is not a good buy right now due to its current price of $5.15, a very low RSI of 29.098 indicating oversold conditions, and a staggering year-to-date change of -63.48%. The company has reported consistent net losses, with the most recent quarterly loss of $1.55 million and a negative EPS of -4.02. The main risk is its declining stock performance, with a 5-day change of -14.88%, suggesting continued downward pressure.

1 analysts cover AEMD: 1 rate it Buy, 0 Hold and 0 Sell.